--- title: "Superior Group Q2 2026 earnings: Branded Products lifts adjusted profit" type: "News" locale: "en" url: "https://longbridge.com/en/news/294922692.md" description: "Superior Group (SGC) reported Q2 2026 net sales of $147.8 million, up 2.6% YoY. While GAAP EPS fell to $0.08 due to a $2.6M non-cash impairment, adjusted EPS more than doubled to $0.21. Branded Products drove growth, offsetting declines in Healthcare Apparel and Contact Centers. Adjusted EBITDA rose 26.6%. The company reaffirmed its full-year 2026 guidance for net sales of $572-$585 million and adjusted diluted EPS of $0.54-$0.66." datetime: "2026-08-05T06:58:41.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294922692.md) - [en](https://longbridge.com/en/news/294922692.md) - [zh-HK](https://longbridge.com/zh-HK/news/294922692.md) --- # Superior Group Q2 2026 earnings: Branded Products lifts adjusted profit Superior Group of Companies (NASDAQ: SGC) reported Q2 2026 net sales of $147.8 million, up about 2.6% from $144.0 million, while diluted GAAP EPS fell to $0.08 from $0.10. The quarter ended June 30 was affected by a $2.6 million non-cash Healthcare Apparel tradename impairment; excluding that charge, adjusted EPS more than doubled to $0.21. Branded Products supplied the main growth, while Healthcare Apparel and Contact Centers recorded lower sales. ## Core earnings data Revenue growth was modest, and gross profit increased more slowly than sales as gross margin edged down. However, selling and administrative expenses declined to $51.3 million from $52.2 million, helping adjusted EBITDA and its margin improve. The impairment charge reduced reported earnings by $2.0 million after tax, or $0.13 per diluted share. Because the charge was excluded from adjusted results, GAAP and adjusted earnings moved in opposite directions. Metric Q2 2026 Q2 2025 Year-over-year change Net sales $147.8 million $144.0 million About +2.6% Gross profit $56.1 million $55.3 million About +1.4% Gross margin About 38.0% About 38.4% About -0.4 percentage points Net income $1.2 million $1.6 million About -21.3% Diluted GAAP EPS $0.08 $0.10 \-20.0% Adjusted net income $3.2 million $1.6 million About +105.1% Adjusted diluted EPS $0.21 $0.10 +110.0% Adjusted EBITDA and margin $7.7 million; 5.2% $6.1 million; 4.2% About +26.6%; +1.0 percentage point ## Business and segment performance Branded Products accounted for the company’s overall sales growth and most of the improvement in segment profitability. Healthcare Apparel moved from a positive segment adjusted EBITDA contribution to a small loss, while Contact Centers increased segment adjusted EBITDA despite lower revenue. Segment Q2 2026 sales Q2 2025 sales Sales change Q2 2026 segment adjusted EBITDA Q2 2025 segment adjusted EBITDA Branded Products $98.4 million $92.6 million About +6.2% $11.2 million $9.0 million Healthcare Apparel $27.2 million $28.3 million About -3.6% $(0.2) million $0.8 million Contact Centers $23.1 million $24.0 million About -3.7% $2.0 million $1.6 million Segment sales exclude the effect of intersegment eliminations. Branded Products’ segment adjusted EBITDA rose about 24.9%, while Contact Centers’ increased about 24.7%. By contrast, Healthcare Apparel’s segment adjusted EBITDA deteriorated by approximately $1.0 million before considering the separate tradename impairment. ## Lower SG&A lifted adjusted profit, while impairment reduced GAAP earnings The quarter’s central earnings issue was the gap between improving underlying profitability and declining reported profit. Gross profit increased by approximately $0.8 million, while selling and administrative expenses decreased by roughly $0.9 million. Those changes supported the increase in adjusted EBITDA despite only modest revenue growth and a slight decline in gross margin. The $2.6 million Healthcare Apparel tradename impairment then reduced GAAP earnings. Management said the non-cash charge did not affect cash, operating cash flow or compliance with bank debt covenants. Adjusted net income therefore rose by approximately $1.6 million, even as reported net income fell by about $0.3 million. ## Cash flow and balance sheet Cash flow figures were provided for the first six months of 2026 rather than the second quarter alone. First-half operating cash flow increased to $17.7 million from $2.9 million a year earlier. Accounts receivable contributed $9.1 million of cash, and inventory changes contributed $2.4 million, partly offset by an $8.2 million increase in contract assets. Cash and equivalents were $22.8 million at June 30, 2026, compared with $23.7 million at the end of 2025. Current and long-term debt totaled approximately $82.0 million, down from $93.7 million at year-end. During the first half, SGC used $11.7 million for revolver and term-loan repayments, $4.4 million for dividends and $0.8 million for share repurchases. Inventories declined to $90.5 million from $97.5 million at year-end. However, first-half inventory write-downs rose to $4.7 million from $1.0 million, an item investors may need to monitor alongside future gross-margin performance. The board also declared a quarterly dividend of $0.14 per share, payable August 28, 2026, to shareholders of record on August 14. ## Full-year guidance SGC reaffirmed rather than raised its full-year 2026 outlook. Management continues to expect stronger second-half results because of seasonal factors, making execution later in the year important to reaching the stated ranges. Metric 2026 outlook 2025 actual Approximate implied growth Status Net sales $572.0 million-$585.0 million $566.2 million About 1.0%-3.3% Reaffirmed Adjusted diluted EPS $0.54-$0.66 $0.46 About 17.4%-43.5% Reaffirmed ## Management’s view CEO Michael Benstock said the company is operating through soft market conditions but continues to see growth opportunities across all three segments. Management emphasized the company’s diversified end markets, customer retention, flexible supply chain and balance sheet, while identifying Branded Products as the quarter’s strongest performer. ## Recent insider transaction Recent insider data showed no open-market purchase or sale transactions during the preceding six months. One recent transaction with a stated amount was a stock award to an officer, which should be distinguished from an open-market purchase. Date Insider Role Transaction Reported price Reported amount May 14, 2026 Dominic Leide Officer Stock award/grant $11.75 per share $224,836 The award alone does not provide a basis for inferring management’s view of the stock’s valuation or outlook. ## Risks investors should watch - **Soft demand:** Management described market conditions as soft, while Healthcare Apparel and Contact Centers both reported lower quarterly sales. - **Healthcare Apparel pressure:** The segment moved to a small adjusted EBITDA loss and recorded a $2.6 million tradename impairment, making a recovery in its profitability an important operating issue. - **Second-half dependence:** The full-year outlook assumes stronger results later in 2026 due to seasonality. A weaker-than-planned second half could make the guidance ranges harder to achieve. - **Inventory valuation and margin:** First-half inventory write-downs rose to $4.7 million, and quarterly gross margin declined by about 0.4 percentage points despite higher sales. ## Summary Superior Group’s Q2 2026 results showed modest revenue growth and stronger adjusted profitability, led by Branded Products and lower selling and administrative expenses. A non-cash Healthcare Apparel impairment caused GAAP earnings to decline and highlighted continued pressure in that segment. The main items to monitor are Healthcare Apparel’s recovery, inventory write-downs and whether seasonal improvement in the second half is sufficient to deliver the reaffirmed full-year outlook. Find out more ### Related Stocks - [SGC.US](https://longbridge.com/en/quote/SGC.US.md) ## Related News & Research - [SGC: Q2 2026 saw higher sales, improved adjusted EBITDA, and a $0.14 dividend, despite an impairment](https://longbridge.com/en/news/294815863.md) - [Superior Group of Companies (NASDAQ:SGC) Posts Quarterly Earnings Results](https://longbridge.com/en/news/294832376.md) - [Corcept CFO Atabak Mokari sells 79,000 shares worth $8.95 million](https://longbridge.com/en/news/294736369.md) - [NAGE: Q2 2026 delivered $29.8M sales, $1M net income, and major telehealth and pharma launches](https://longbridge.com/en/news/294864217.md) - [Viromed Medical: Heike Perbandt, closely associated with CEO Uwe Perbandt, sells shares for EUR 38,000](https://longbridge.com/en/news/294717192.md)